135 related articles for article (PubMed ID: 11834972)
1. Probable interaction between efavirenz and cyclosporine.
Tseng A; Nguyen ME; Cardella C; Humar A; Conly J
AIDS; 2002 Feb; 16(3):505-6. PubMed ID: 11834972
[No Abstract] [Full Text] [Related]
2. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Yazaki H; Kikuchi Y; Oka S
Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
[No Abstract] [Full Text] [Related]
3. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
Tenorio AR; Irlanda IE; Narkiewicz E; Smith KY; Kessler HA; Sha BE
AIDS; 2000 Jul; 14(10):1470-1. PubMed ID: 10930173
[No Abstract] [Full Text] [Related]
5. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
[No Abstract] [Full Text] [Related]
6. Dose-ranging studies.
Manion D
Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
[TBL] [Abstract][Full Text] [Related]
7. Methadone withdrawal symptoms with nevirapine and efavirenz.
Pinzani V; Faucherre V; Peyriere H; Blayac JP
Ann Pharmacother; 2000 Mar; 34(3):405-7. PubMed ID: 10917395
[No Abstract] [Full Text] [Related]
8. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
[TBL] [Abstract][Full Text] [Related]
9. [Long-term success in routine clinical practice. Effectiveness trial passed].
MMW Fortschr Med; 2000; 142(3 Suppl):30-1. PubMed ID: 10893961
[No Abstract] [Full Text] [Related]
10. Recurrence of post-traumatic stress disorder and antiretrovirals.
Damsa C; Bandelier C; Maris S; Lazignac C; Vidailhet P; Andreoli A; Bianchi-Demicheli F
Scand J Infect Dis; 2005; 37(4):313-6. PubMed ID: 15880881
[TBL] [Abstract][Full Text] [Related]
11. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Soriano V; Dona C; Barreiro P; González-Lahoz J
AIDS; 2000 Jul; 14(11):1672-3. PubMed ID: 10983663
[No Abstract] [Full Text] [Related]
12. Efavirenz-associated breast hypertrophy in HIV-infection patients.
Mercié P; Viallard JF; Thiébaut R; Faure I; Rispal P; Leng B; Pellegrin JL
AIDS; 2001 Jan; 15(1):126-9. PubMed ID: 11192857
[No Abstract] [Full Text] [Related]
13. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
Wolbach J; Capoccia K
Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
[No Abstract] [Full Text] [Related]
14. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
15. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.
Boffito M; Rossati A; Reynolds HE; Hoggard PG; Back DJ; Di Perri G
AIDS Res Hum Retroviruses; 2002 Mar; 18(5):341-2. PubMed ID: 11897035
[No Abstract] [Full Text] [Related]
16. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
17. Efavirenz-associated podocyte damage.
Barbour TD; Furlong TJ; Finlayson RJ
AIDS; 2007 Jan; 21(2):257-8. PubMed ID: 17197824
[No Abstract] [Full Text] [Related]
18. Decreased nephrotoxicity after the use of a microemulsion formulation of cyclosporine A compared to conventional solution.
Ahlmén J; Sundberg A; Gustavsson A; Strömbom U
Transplant Proc; 1995 Dec; 27(6):3432-3. PubMed ID: 8540036
[No Abstract] [Full Text] [Related]
19. A once-daily combination tablet (Atripla) for HIV.
Med Lett Drugs Ther; 2006 Sep; 48(1244):78-9. PubMed ID: 17001298
[No Abstract] [Full Text] [Related]
20. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
